Clinical Trials by Condition - BlackDoctor

Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo

Condition: Non-Segmental Vitiligo

Testing For: XCL1/2 (LY4005130)

Trial ID: J5D-MC-FPAD

Age: 18 to ≤75 years of age

Phase: 2

Learn More

Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Severe Alopecia Areata

Condition: Severe Alopecia Areata

Testing For: XCL1/2 (LY4005130)

Trial ID: J5D-MC-FPAC

Age: 18 to ≤50 years of age

Phase: 2

Learn More

EMERALD-3: A Phase 2b/3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis

Condition: Ulcerative Colitis

Testing for: LY4268989 (MORF-057)

Trial ID: J6E-MC-KWAM

Age: 18 - 80

Phase: 2 and 3

Learn More

We’re helping to connect individuals with a clinical study for adults living with uncontrolled gout. Uncontrolled gout occurs when gout symptoms keep coming back despite taking medication, causing repeated flare-ups, lingering joint pain, and sometimes hard lumps under the skin called tophi.

The Kadence study is being conducted to evaluate the safety and efficacy of the study drug administered as a subcutaneous injection compared to an IV infusion in adults with uncontrolled gout. If approved, the subcutaneous administration of the study drug may offer a more convenient approach to managing uncontrolled gout.

This study is looking for about 270 adults who have been diagnosed with uncontrolled gout to participate.

What to Expect

• Regular visits and follow ups with a study team

• Study drug administration

• Safety monitoring

• Support from a study team

Why Consider Participating

• Every participant receives the study drug at no charge using one of two delivery methods

• Access to physicians with experience working with gout

• Reasonable reimbursements for travel-related expenses may be available

• Potentially help move research forward for other people with goutcipate.

Condition: Gout

Learn More

A Two-Part Phase 3 Study of LY4170156 in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01)

Condition: Ovarian Cancer

Testing for: LY4170156, mirvetuximab soravtansine, topotecan, bevacizumab, paclitaxel, carboplatin, gemcitabine

Trial ID: J5E-MC-JZXB

Age: ≥18 years

Phase: 3

Learn More

FORAGER-2 Study: A clinical research study for people living with bladder cancer and a change in the FGFR3 gene

Condition: Bladder Cancer

A Study Investigating Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Trial ID: J4G-MC-JZVD

Age: ≥18 years

Phase: 3

Learn More

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy andsafety of zanidatamab in combination with physician’s choice chemotherapy compared totrastuzumab in combination with physician’s choice chemotherapy for the treatment ofparticipants with metastatic HER2-positive breast cancer who have progressed on, or areintolerant to, previous trastuzumab deruxtecan treatment

Condition: Metastatic HER2-Positive Breast Cancer

Study Number: JZP598-303 - Protocol and Amendment Number: JZP598-303-02

Drugs: Zanidatamab

Phase: 3

Learn More

Dapirolizumab pegol as an add-on treatment in adults and teens with moderate to severe SystemicLupus Erythematosus (SLE)

Drugs: Dapirolizumab pegol

Trial ID: PHOENYCS FLY STUDY for Adults & Teens Living with Lupus – SL0044

Age: 16+ Years Old

Phase: 3

Learn More

Assess the safety and effectiveness of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe, native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease, who are judged by a multi-disciplinary heart team to be at high risk for open surgical aortic valve replacement (SAVR). Condition: Symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease.

Condition: Aortic Valve Regurgitation (AR)

Trial ID: J-Valve Transfemoral Pivotal Study (JOURNEY) Testing For: The safety and effectiveness of the J-Valve Transfemoral (TF)

Learn More

Assess the safety and effectiveness of the J-ValveTransfemoral (TF) System in patients with symptomatic, severe, native aorticvalve regurgitation (AR) and AR-dominant mixed aortic valve disease, whoare judged by a multi-disciplinary heart team to be at high risk for opensurgical aortic valve replacement (SAVR).

Condition: Symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease.

The safety and effectiveness of the J-Valve Transfemoral (TF) System

Trial ID: J-Valve Transfemoral Pivotal Study (JOURNEY)

Learn More

DeLLphi-312 is a Phase 3 clinical trial that is testing an investigational drug called tarlatamab. This clinical trial aims to see how safe and effective tarlatamab is at treating patients with small-cell lung cancer (SCLC). Participants will receive either tarlatamab in combination with durvalumab (Imfinzi®), carboplatin and etoposide, or durvalumab, carboplatin and etoposide alone.

Condition: Small-cell lung cancer (SCLC)

Trial ID: DeLLphi-312

Age: 18+ years old

Phase: 3

Learn More

TOPAZ-UC: A Phase 2, Multicenter, Randomized, Double-Blind, Active- Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis

Condition: Ulcerative Colitis

Drugs: LY4268989 (MORF-057) and Mirikizumab (LY3074828)

Trial ID: J6E-MC-KWAN

Age: 18-80

Phase: 2

Learn More

HIV and The Gut Microbiome: Prebiotics and Probiotics

FDA’s New Real-Time Clinical Trial Monitoring Could Speed Up Access to Lifesaving Treatments

Doctors Told Her to End Her Pregnancy—Until She Got a Second Opinion

Clinical Trials

Where Culture Meets Care

Clinical Trials

Where Culture Meets Care

Download PDF